Warrior Met Coal LLC(HCC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HCC Warrior Met Coal LLC

交易中 09-25 12:08:11 EDT

88.51

-0.44

-0.49%

最高89.08	最低87.34	成交量9.41万
今开88.54	昨收88.95	日振幅1.96%
总市值46.53亿	流通市值45.83亿	总股本5,257万
成交额830.95万	换手率0.18%	流通股本5,178万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HCC","market":"US","secType":"STK","nameCN":"Warrior Met Coal LLC","latestPrice":88.51,"timestamp":1790352487249,"preClose":88.95,"halted":0,"volume":94055,"delay":0,"changeRate":-0.004946599213041009,"floatShares":51775204,"shares":52570156,"eps":4.16,"marketStatus":"交易中","change":-0.44,"latestTime":"09-25 12:08:11 EDT","open":88.535,"high":89.08,"low":87.3376,"amount":8309546.6857,"amplitude":0.019589,"askPrice":88.6,"askSize":211,"bidPrice":88.42,"bidSize":10,"shortable":3,"etf":0,"ttmEps":4.16,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790366400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":720248400000,"exchange":"NYSE","adjPreClose":88.95,"dividendRate":0.003615,"preHourTrading":{"tag":"盘前","latestPrice":88.675,"preClose":88.95,"latestTime":"09:28 EDT","volume":162,"amount":14443.338419999998,"timestamp":1790342897334,"change":-0.275,"changeRate":-0.003092,"amplitude":0.033727},"postHourTrading":{"tag":"盘后","latestPrice":88.95,"preClose":88.95,"latestTime":"19:30 EDT","volume":14970,"amount":1331579.048,"timestamp":1790292604460,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.276435,"impliedVol":0.53,"impliedVolPercentile":0.3665},"requestUrl":"/m/hq/s/HCC","defaultTab":"news","newsList":[{"id":"2662008845","title":"宜明昂科-B(01541)：IMM2510联合IMM27M一线治疗晚期HCC的II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662008845?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:21","pubTimestamp":1787836891,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM2510联 合 IMM27M一线治疗晚期肝细胞癌患者的II期临床试验顺利完成首例患者给药。该研究旨在评估IMM2510联合IMM27M在该患者群体中的初步疗效及安全性。自2023年首次提交IMM2510联合IMM27M的试验性新药申请以来，该联合疗法的临床开发稳步推进，并展现出卓越的潜力。令人鼓舞的早期临床结果证实，IMM2510联合IMM27M在晚期实体瘤治疗中具有显著的抗肿瘤活性及可控的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["COAL","PSYK","IBBQ","BMED","MDTX","IBBJ","01541","HCC","BK1161","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657069571","title":"维立志博-B(09887.HK)：维利信™用于治疗肝细胞癌的Ⅱ期研究顺利进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2657069571","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657069571?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:17","pubTimestamp":1785968230,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HCC","COAL","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127576867","title":"Warrior Met Coal 第二季度净利润达 8740 万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127576867","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127576867?lang=zh_cn&edition=full","pubTime":"2026-08-06 04:25","pubTimestamp":1785961559,"startTime":"0","endTime":"0","summary":"8月5日，Warrior Met Coal LLC（简称Warrior Met Coal）公布其第二季度业绩，调整后EBITDA达到1.569亿美元。与此同时，该公司的净利润为8740万美元，展现出稳健的盈利表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","COAL","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170751811","title":"财报前瞻｜Warrior Met Coal LLC本季度营收预计增66.90%，机构看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1170751811","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170751811?lang=zh_cn&edition=full","pubTime":"2026-07-29 12:42","pubTimestamp":1785300135,"startTime":"0","endTime":"0","summary":"Warrior Met Coal LLC将于2026年08月05日美股盘后发布新季度财报，市场预计本季度收入和盈利延续增长，机构观点偏向积极。市场一致预期显示，本季度Warrior Met Coal LLC收入预计为4.87亿美元，同比增长66.90%；调整后每股收益预计为1.48美元，同比增长6.48%；同时，EBIT预计为0.84亿美元，同比增长5.36%。上季度Warrior Met Coal LLC实现营收4.59亿美元，同比增长55.49%；毛利率34.85%；归属于母公司股东的净利润0.72亿美元，净利率15.77%；调整后每股收益1.37美元，同比增长9.56%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Warrior Met Coal LLC本季度营收预计增66.90%，机构看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654395072","title":"Sonesitatug vedotin 在 CLDN18.2阳性晚期胃癌/胃食管结合部癌的二线及后线治疗中，显示出具有统计学显著性且重要临床意义的总生存期（OS）改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2654395072","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654395072?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:18","pubTimestamp":1785212280,"startTime":"0","endTime":"0","summary":"关于胃癌和胃食管结合部癌 胃癌是全球第五大常见癌症，也是癌症相关死亡的第五大原因。关键次要终点为二线及后线治疗人群的总生存期。CLDN18.2是一种存在于胃黏膜上皮中的蛋白，已被验证为肿瘤治疗领域的重要治疗靶点，尤其在胃肠道肿瘤中具有重要意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AZNH","BFJL","ADC","MNRS","BITY","CBTA","BITO","MAXI","CBXA","FBTC","BTFX","IBIT","BTCW","CBXJ","CBTJ","CBTY","YBTC","AZN","BTCO","CBOJ","BETE","EZBC","CBXY","EAC","HCC","BITU","BITI","CBXO","ARKB","BTC","BTCZ","BTCI","BITX","CBOA","BTCL","NETL","CBTO","PFS","HODL","IBBQ","XBTY","IHC","DEFI","BCCC","BRRR","SBIT","COAL","BETH","QBF","BTRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646871144","title":"复宏汉霖(02696)：伊匹木单抗生物类似药HLX13一线治疗不可切除的晚期肝细胞癌(HCC)患者的国际多中心1期临床研究完成美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2646871144","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646871144?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:25","pubTimestamp":1782383143,"startTime":"0","endTime":"0","summary":"HLX13是本公司自主研发的伊匹木单抗生物类似药，拟用于黑色素瘤、肾细胞癌、结直肠癌、肝细胞癌、非小细胞肺癌、恶性胸膜间皮瘤及食管鳞状细胞癌等原研药已获批的适应症。2025年11月，HLX13一线治疗不可切除的肝细胞癌患者的国际多中心1期临床研究于中国境内完成首例患者给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4006","HCC","HK0000165453.HKD","HK0000306701.USD","HK0000306685.HKD","HK0000320223.HKD","BK1161","HK0000320264.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640818021","title":"和誉-B(02256)：和誉医药于PAGE会议展示ABSK-011(依帕戈替尼)在HCC患者中的联合建模新框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2640818021","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640818021?lang=zh_cn&edition=full","pubTime":"2026-06-04 08:04","pubTimestamp":1780531491,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，公司在2026年6月2日至5日于克罗地亚杜布罗夫尼克举行的欧洲群体药理学会议(PAGE会议)上，以壁报形式展示了两项基于模型的药物开发新进展。其中一项报告重点展示了一种创新的联合建模框架，用于预测高选择性FGFR4抑制剂ABSK-011(依帕戈替尼)在晚期FGF19+肝细胞癌(HCC)患者中的无进展生存期(PFS)。此外，和誉医药与外部合作方共同展示了一项基于国内自主研发的创新建模软件Maspectra完成的ABSK-011群体药代动力学建模研究，其中包括与NONMEM的比较分析。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4006","02256","HCC","LU2476274308.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","159938","LU2488822045.USD","BK1515","09939","BK1161","IE00BPRC5H50.USD","BK1574","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640980032","title":"中国药企“炸场”全球肿瘤年度盛会！多款原研药改写治疗标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640980032","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640980032?lang=zh_cn&edition=full","pubTime":"2026-06-01 12:09","pubTimestamp":1780286940,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛2026年5月29日至6月2日，芝加哥麦考密克展览中心再次迎来全球肿瘤学领域最权威的年度盛会——美国临床肿瘤学会（ASCO）年会。全球超过4万名肿瘤学专家齐聚于此，共同探讨、分享当前国际最前沿的科研成果与治疗技术。而这一届ASCO，注定在61年的年会历史上留下浓墨重彩的一笔——来自中国的声音，正在以前所未有的分量，改写着全球肿瘤治疗版图的权力结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755851626.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755851626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TACE","BK4006","BK1161","BK1574","HCC","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162134419","title":"异动解读 | 中美贸易限制与全球供应过剩施压，Warrior Met Coal盘后大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162134419","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162134419?lang=zh_cn&edition=full","pubTime":"2026-05-01 05:05","pubTimestamp":1777583126,"startTime":"0","endTime":"0","summary":"冶金煤生产商Warrior Met Coal LLC（HCC）今日盘后股价大跌5.22%，引起了市场关注。消息面上，该公司持续面临中美贸易壁垒的制约，出口业务受限难以充分开拓亚太关键市场。同时，全球市场供应充裕的格局不断加剧其产品定价压力，主要产煤国增产导致高品质硬焦煤价格承压，压缩了冶金煤生产商的利润空间。随着澳大利亚、蒙古等国出口量回升，海运煤价与内陆供应价差收窄，北美冶金煤供应商包括Warrior Met Coal需要重新评估其市场竞争策略，这些因素共同影响了投资者对公司短期盈利前景的预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107408877","title":"中美贸易限制持续施压 全球供应过剩加剧Warrior Met Coal定价困境","url":"https://stock-news.laohu8.com/highlight/detail?id=1107408877","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107408877?lang=zh_cn&edition=full","pubTime":"2026-05-01 04:25","pubTimestamp":1777580718,"startTime":"0","endTime":"0","summary":"冶金煤生产商Warrior Met Coal LLC仍面临中美贸易壁垒的持续制约，与此同时全球市场供应充裕的格局不断加剧其产品定价压力。\n行业观察人士指出，尽管国际能源需求逐步回暖，但主要产煤国增产势头未减，导致高品质硬焦煤价格持续承压。该公司出口业务因贸易政策受限，难以充分开拓亚太地区关键市场，使其在全球供应链重构过程中面临严峻挑战。\n市场分析师强调，海运煤价与内陆供应之间的价差收窄，进一步压缩了冶金煤生产商的利润空间。随着澳大利亚、蒙古等国出口量回升，北美冶金煤供应商需要重新评估其市场竞争策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630459395","title":"度伐利尤单抗单药及双免联合方案获批，用于晚期肝细胞癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2630459395","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630459395?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:13","pubTimestamp":1777288380,"startTime":"0","endTime":"0","summary":"新京报讯（记者王卡拉）4月27日，阿斯利康宣布，国家药品监督管理局已正式批准度伐利尤单抗（商品名：英飞凡）联合曲麦利尤单抗（中文商品名：英卓凡）用于晚期或不可切除的肝细胞癌（HCC）成人患者的一线治疗。此外，度伐利尤单抗亦获批单药用于晚期或不可切除的肝细胞癌成人患者的一线治疗。原发性肝细胞癌是全球癌症相关死亡的重要原因之一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720441962.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720441962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194443092","title":"财报前瞻｜Warrior Met Coal LLC本季度营收预计增长67.56%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1194443092","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194443092?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:44","pubTimestamp":1776923087,"startTime":"0","endTime":"0","summary":"Warrior Met Coal LLC将于2026年04月30日发布新季度财报，市场聚焦营收与盈利修复趋势及核心矿区产量释放节奏。市场一致预期显示，本季度Warrior Met Coal LLC营收预计为4.77亿美元，同比增长67.56%；调整后每股收益预计为1.37美元，同比增长272.00%；息税前利润预计为7,864.10万美元，同比增长41.78%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Warrior Met Coal LLC本季度营收预计增长67.56%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627491097","title":"核药“狂飙”：2026年中外巨头激战300亿美元蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2627491097","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627491097?lang=zh_cn&edition=full","pubTime":"2026-04-14 12:54","pubTimestamp":1776142440,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛2026年的春天，核药赛道没有一丝“倒春寒”的迹象。4月中旬，两则消息几乎同时引爆了全球核医学圈。一则是关于“中国原创”的崛起：百洋医药集团孵化企业瑞迪奥研发的99mTc-3PRGD2（吉伦泰）正式获批，这是全球首个用于SPECT显像的广谱肿瘤显像剂，打破了PET技术近30年的垄断。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704207863.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704207863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ORR","CR","HCC","BK4161","BK4006","RDC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627982064","title":"远大医药：易甘泰在美国开展的治疗HCC临床研究达到了临床终点 完全缓解率90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627982064","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627982064?lang=zh_cn&edition=full","pubTime":"2026-04-14 09:44","pubTimestamp":1776131040,"startTime":"0","endTime":"0","summary":"4月13日，远大医药（00512）发布公告，集团联营公司SirtexMedicalPtyLtd的SIR-Spheres钇[Y]微球注射液(\"易甘泰?\")在美国开展的用于治疗不可切除肝细胞癌(\"HCC\")临床研究(\"DOORwaY90研究\")成功达到了临床终点。该研究的结果显示，完全缓解率高达90%，最佳总体缓解率为99%，局部肿瘤控制率达100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704050982.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704050982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4006","BK1191","HCC","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518696201","title":"Can Fite Biopharma Ltd盘中异动 股价大跌5.06%报1.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518696201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518696201?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:00","pubTimestamp":1741629613,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时00分，Can Fite Biopharma Ltd股票出现异动，股价快速下跌5.06%。截至发稿，该股报1.50美元/股，成交量3.0409万股，换手率0.50%，振幅6.82%。Can Fite Biopharma Ltd股票所在的生物技术行业中，整体涨幅为0.78%。Can Fite Biopharma Ltd公司简介：Can Fite Biofarma Ltd 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311020014a26a8866&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311020014a26a8866&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CANF","HCC","BK4006","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516603010","title":"Can Fite Biopharma Ltd盘中异动 快速下跌6.98%报1.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516603010","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516603010?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:24","pubTimestamp":1741101861,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时24分，Can Fite Biopharma Ltd股票出现异动，股价大幅跳水6.98%。截至发稿，该股报1.60美元/股，成交量2.0657万股，换手率0.34%，振幅2.91%。Can Fite Biopharma Ltd股票所在的生物技术行业中，整体涨幅为0.39%。Can Fite Biopharma Ltd公司简介：Can Fite Biofarma Ltd 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232422989bbade&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232422989bbade&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CANF","BK4139","HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516344716","title":"Warrior Met Coal, Inc.盘中异动 早盘急速拉升5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516344716","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516344716?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:33","pubTimestamp":1741012427,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时33分，Warrior Met Coal, Inc.股票出现波动，股价急速拉升5.23%。截至发稿，该股报50.66美元/股，成交量2.0078万股，换手率0.04%，振幅0.53%。Warrior Met Coal, Inc.股票所在的焦练煤行业中，整体涨幅为1.28%。其相关个股中，Warrior Met Coal, Inc.、Ramaco Resources, Inc.、Suncoke Energy, Inc.涨幅较大，American Resources Corporation、Warrior Met Coal, Inc.、Alpha Metallurgical Resources, Inc.较为活跃，换手率分别为0.64%、0.04%、0.03%，振幅较大的相关个股有American Resources Corporation、Ramaco Resources, Inc.、Suncoke Energy, Inc.，振幅分别为3.93%、2.24%、0.61%。Warrior Met Coal, Inc.公司简介：Warrior Met Coal Inc是一家总部位于美国的公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223347989a1010&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223347989a1010&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514376958","title":"Can Fite Biopharma Ltd盘中异动 大幅上涨5.11%报1.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514376958","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514376958?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:45","pubTimestamp":1740757506,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时45分，Can Fite Biopharma Ltd股票出现异动，股价急速上涨5.11%。截至发稿，该股报1.85美元/股，成交量3.043万股，换手率0.50%，振幅4.32%。Can Fite Biopharma Ltd股票所在的生物技术行业中，整体涨幅为0.19%。Can Fite Biopharma Ltd公司简介：Can Fite Biofarma Ltd 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228234506abe0fc16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228234506abe0fc16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","HCC","CANF","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513720452","title":"Can Fite Biopharma Ltd盘中异动 大幅下挫6.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720452","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513720452?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:05","pubTimestamp":1740409507,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时05分，Can Fite Biopharma Ltd股票出现异动，股价大幅下挫6.07%。截至发稿，该股报1.70美元/股，成交量2.9367万股，换手率0.48%，振幅5.25%。Can Fite Biopharma Ltd股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Pepgen Inc.、Telix Pharmaceutic、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为161.52%、71.01%、25.66%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、42.86%。Can Fite Biopharma Ltd公司简介：Can Fite Biofarma Ltd 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242305089890fe29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242305089890fe29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCC","CANF","BK4139","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513722744","title":"Warrior Met Coal, Inc.盘中异动 早盘大幅拉升11.71%报51.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513722744?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:31","pubTimestamp":1740407497,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时31分，Warrior Met Coal, Inc.股票出现异动，股价快速拉升11.71%。截至发稿，该股报51.53美元/股，成交量17.3023万股，换手率0.33%，振幅4.15%。Warrior Met Coal, Inc.股票所在的焦练煤行业中，整体涨幅为4.38%。其相关个股中，Warrior Met Coal, Inc.、Alpha Metallurgical Resources, Inc.、American Resources Corporation涨幅较大，Warrior Met Coal, Inc.、American Resources Corporation、Alpha Metallurgical Resources, Inc.较为活跃，换手率分别为0.33%、0.07%、0.04%，振幅较大的相关个股有Warrior Met Coal, Inc.、American Resources Corporation、Ramaco Resources, Inc.，振幅分别为4.15%、3.43%、1.44%。Warrior Met Coal, Inc.公司简介：Warrior Met Coal Inc 是一家美国公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223137abdb0dbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223137abdb0dbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.warriormetcoal.com","stockEarnings":[{"period":"1week","weight":-0.031},{"period":"1month","weight":-0.1552},{"period":"3month","weight":0.0944},{"period":"6month","weight":-0.103},{"period":"1year","weight":0.4262},{"period":"ytd","weight":0.0088}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.2099},{"period":"1year","weight":0.1605},{"period":"ytd","weight":0.125}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Warrior Met Coal, Inc.于2015年9月3日成立于特拉华州，是总部位于阿拉巴马州布鲁克伍德的全球钢铁行业的美国环保和社会意识供应商。他们完全致力于开采非热炼钢煤，这些煤是欧洲、南美和亚洲金属制造商钢铁生产的关键组成部分。他们是一家大规模、低成本的优质冶金或炼钢煤生产商和出口商。","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.047428},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.016436},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.028693},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.010079},{"month":5,"riseRate":0.5,"avgChangeRate":0.016174},{"month":6,"riseRate":0.6,"avgChangeRate":-0.005518},{"month":7,"riseRate":0.7,"avgChangeRate":0.066127},{"month":8,"riseRate":0.5,"avgChangeRate":0.054739},{"month":9,"riseRate":0.6,"avgChangeRate":0.013521},{"month":10,"riseRate":0.555556,"avgChangeRate":0.03995},{"month":11,"riseRate":0.666667,"avgChangeRate":0.081356},{"month":12,"riseRate":0.777778,"avgChangeRate":0.058477}],"exchange":"NYSE","name":"Warrior Met Coal LLC","nameEN":"Warrior Met Coal LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Warrior Met Coal LLC(HCC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Warrior Met Coal LLC(HCC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Warrior Met Coal LLC,HCC,Warrior Met Coal LLC股票,Warrior Met Coal LLC股票老虎,Warrior Met Coal LLC股票老虎国际,Warrior Met Coal LLC行情,Warrior Met Coal LLC股票行情,Warrior Met Coal LLC股价,Warrior Met Coal LLC股市,Warrior Met Coal LLC股票价格,Warrior Met Coal LLC股票交易,Warrior Met Coal LLC股票购买,Warrior Met Coal LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Warrior Met Coal LLC(HCC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Warrior Met Coal LLC(HCC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}